Medindia LOGIN REGISTER
Medindia

Glenmark and GBR401

by Savitha C Muppala on Apr 1 2011 8:30 PM

 Glenmark and GBR401
The discovery and initiated IND enabling studies of a Novel Biological Entity (NBE) lead candidate, GBR401 and anti-CD19 monoclonal antibody, has been announced by Glenmark Pharmaceuticals SA (GPSA), a wholly owned subsidiary of Glenmark Pharmaceuticals India.
The brain-child of Glenmark's Biologics Research Centre, GBR 401 helps in targeting diseases like lymphomas and leukemia's of B-cell origin.



Source-Medindia


Advertisement